![1/8/2015 Aradigm
http://www.aradigm.com/ 1/2
We are Fulfilling
Unmet Needs in
Pulmonary Medicine.
Aradigm is an emerging specialty
pharmaceutical company developing and
commercializing a portfolio of drugs delivered
by inhalation for the treatment of severe
respiratory disease.
Bolstered by its depth of expertise in
pulmonary drug delivery and an extensive
intellectual property portfolio, the Company is
uniquely positioned to fulfill unmet needs in
pulmonary medicine. Our corporate strategy
includes the following:
• Continued development of proprietary
respiratory disease therapies
• Pursue regulatory pathways that reduce the
time, costs and risks associated with product
development
• Conservation of capital for proprietary
product development through the outsourcing
of late stage clinical and commercial scale
manufacturing
• Deployment of a specialized sales and
marketing force to meet the unique needs of
pulmonologists in the United States
• Out-licensing technology and intellectual
property assets for applications that lie outside
the company's strategic interests and core
expertise
CLINICAL TRIALS
News & Events
Aradigm to Present at the Stifel Healthcare
Conference 2014
[12NOV14]
Stifel Healthcare Conference 2014 Webcast
[12NOV14]
Aradigm Announces Third Quarter 2014
Financial Results
[07NOV14]
FDA Grants Fast Track Designation to
Aradigm's Pulmaquin for Non-Cystic Fibrosis
Bronchiectasis
[04SEP14]
More News >>](https://image.slidesharecdn.com/smokingcessationnon-cfbronchiectasis-150112003033-conversion-gate02/85/Smoking-cessation-non-cf-bronchiectasis-1-320.jpg)
Recommended
Recommended
More Related Content
Viewers also liked
Viewers also liked (12)
Similar to Smoking cessation & non cf bronchiectasis
Similar to Smoking cessation & non cf bronchiectasis (20)
Recently uploaded
Recently uploaded (20)
Smoking cessation & non cf bronchiectasis
- 1. 1/8/2015 Aradigm http://www.aradigm.com/ 1/2 We are Fulfilling Unmet Needs in Pulmonary Medicine. Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following: • Continued development of proprietary respiratory disease therapies • Pursue regulatory pathways that reduce the time, costs and risks associated with product development • Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing • Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States • Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise CLINICAL TRIALS News & Events Aradigm to Present at the Stifel Healthcare Conference 2014 [12NOV14] Stifel Healthcare Conference 2014 Webcast [12NOV14] Aradigm Announces Third Quarter 2014 Financial Results [07NOV14] FDA Grants Fast Track Designation to Aradigm's Pulmaquin for Non-Cystic Fibrosis Bronchiectasis [04SEP14] More News >>
- 2. 1/8/2015 Aradigm http://www.aradigm.com/ 2/2 CONTACT NEWS & EVENTS LEGAL SITE MAP ©2013 A radigm C orporation. A ll Rights Reserved.